Healthcare review: Rosetta Genomics, Rockwell Medical, InterMune, Hansen Medical, Nektar Therapeutics Are Notable Movers Print E-mail
By Staff and Wire Reports   
Friday, 23 November 2012 12:44
U.S. stocks rose for a fifth day during a holiday-shortened, thin trading session on Friday, as investors bid up large technology stocks which had fallen to more attractive levels recently.

Market participants were also encouraged by signs of progress in talks about releasing aid to debt-saddled Greece, and piled into U.S. retail shares as the holiday shopping season got underway.

Following are the notable movers at mid day on Friday:

Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG)
shares climbed 11.84% to $4.77 in the early hour. The company’s third quarter sales increased 6% to $12.7 million, as compared to third quarter 2011. Gross profit increased 19.6% or $0.3 million over third quarter of 2011. Net loss was ($17.9) million compared to ($5.0) million in third quarter of 2011 primarily due to higher R&D expense.

Rockwell Medical Inc. (NASDAQ:RMTI)
shares jumped 11.64% to $7.16. The company issued its quarterly earnings data recently. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by $0.36. The company had revenue of $12.70 million for the quarter, compared to the consensus estimate of $12.57 million.

InterMune, Inc. (NASDAQ:ITMN)
stock gained 6.47% to $9.22. The company reported third-quarter net loss of $45.4 million or $0.70 per share, compared to $38.2 million or $0.63 per share in the same quarter last year. Analysts expected a loss of $0.84 per share. Total revenues for the quarter rose to $7.5 million from $0.1 million last year. Analysts estimated revenues of $6.16 million

Hansen Medical, Inc. (NASDAQ:HNSN)
stock increased 4.65% to $2.25. The company is scheduled to present at the 24th Annual Piper Jaffray Healthcare Conference. The conference is being held November 27-28, 2012, at the New York Palace Hotel, in New York, NY. Hansen Medical is scheduled to present on Wednesday, November 28, 2012 at 2:30 p.m. Eastern Time.

Nektar Therapeutics (NASDAQ:NKTR) shares fell 3.94% to $6.10 in the early hour. The FDA raised concerns that a class of opioid constipation medications may cause heart problems. The company said that the FDA's heart-safety concerns could cast new risks and uncertainties over the development of its constipation medication known as naloxegol or NKTR-118.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter